ArticleBMC nephrology2026
Gut microbiota dysbiosis in intensive care unit patients with acute kidney injury: insights from 16S sequencing and mediation analysis.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe gut-kidney axis is critical in acute kidney injury (AKI) pathophysiology, but its specific characteristics in intensive care unit (ICU) patients remain unclear. This study aimed to investigate compositional and functional alterations of gut microbiota in AKI patients.
methodsPatients were divided into AKI and non_AKI groups. Rectal swabs were collected within 24 h of ICU admission. 16SrDNA sequencing was performed to assess taxonomic composition. Alpha diversity, beta diversity, and Linear discriminant effect size analysis (LEfSe) analyses were conducted. Redundancy analysis (RDA) examined relationships between microbial communities and environmental factors. PICRUSt2 inferred metabolic functional differences. Average causal mediation effect (ACME) analysis explored relationships among dysbiosis, metabolic function, and clinical factors.
resultsA total of 193 individuals comprising 142 AKI and 51 non_AKI were enrolled in the study. Compared to non_AKI patients, the AKI group exhibited significantly higher gut microbiota species richness as measured by the ace index (p < 0.05), indicating an increase in moderately abundant species potentially including opportunistic pathogens. However, no significant differences were observed in chao1 index (another measure of richness), nor in the shannon and simpson indices (measures of overall diversity and evenness), suggesting that while certain bacterial populations expanded, the fundamental structure and balance of the gut ecosystem remained preserved. Significant differences in overall community composition (beta diversity, p < 0.05) were observed between groups. LEfSe identified AKI-associated dysbiosis characterized by proliferation of opportunistic pathogens (e.g., s__Staphylococcus haemolyticus, s__Ruminococcus bromii, and g__Veillonella) and extraintestinal bacterial intrusion (e.g., s__Sneathia amrii, s__Atopobium vaginae). RDA showed that serum creatinine (SCr, r² = 0.079, p = 0.006) and blood urea nitrogen (BUN, r² = 0.066, p = 0.007) were the only clinical factors significantly impacting microbial community structure. PICRUSt2 revealed significant functional alterations between groups, with multiple metabolic pathways (including URSIN-PWY, PWY-5420, PWY-5415, PWY-7854, PWY-5367, TYRFUMCAT-PWY, PWY-5181, PWY-7480, and PWY-5430) showing differential abundance. Exploratory mediation analysis constructed a potential association network linking gut microbiota dysbiosis, altered metabolic pathways, and SCr levels.
conclusionsAKI patients exhibited gut microbiota dysbiosis characterized by opportunistic pathogen proliferation and extraintestinal bacterial intrusion. These alterations were observed in association with disease severity and could potentially relate to SCr levels, possibly via modulation of specific metabolic pathways.
trial registrationThis research was based on the analysis of hospital-acquired infection surveillance data and was not registered in a clinical trial registry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.